Journal of the American Academy of Dermatology · 2026
Efficacy and safety of fish oil supplementation combined with low-dose isotretinoin for moderate-to-severe acne vulgaris: A randomized controlled non-inferiority trial.
СтатьяРандомизированное исследованиеEquivalence TrialНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sungkhasunya Parnpetch, Asawanonda Pravit, Kumtornrut Chanat
Аннотация
BACKGROUND: Isotretinoin is a treatment for moderate-to-severe acne, but it is limited by side effects. Fish oil may reduce these side effects; however, its impact on the clinical efficacy and safety of low-dose isotretinoin in the treatment of acne vulgaris has not been evaluated.
OBJECTIVE: To compare the efficacy and safety of low-dose isotretinoin combined with fish oil versus low-dose isotretinoin monotherapy in moderate-to-severe acne.
METHODS: In this randomized, double-masked, controlled, non-inferiority trial, participants aged 18 to 25 years with an acne Investigator's Global Assessment (IGA) score ≥3 received 10-mg isotretinoin with 1-g fish oil (n = 40) or placebo (n = 40) once daily for 3 months. Outcomes included acne counts, IGA scores, skin biophysics, mucocutaneous adverse effects, serum triglyceride (TG), and liver transaminases.
RESULTS: The fish oil group was noninferior to the placebo group in reducing total acne counts from baseline (between-group mean difference: -6.0; 95% CI: -16.5 to 4.5). Fish oil also showed smaller reductions in corneometer values and smaller increases in TG levels.
LIMITATIONS: The use of IGA-based inclusion criteria may have influenced the non-inferiority analysis and the 3-month duration may limit long-term interpretation.
CONCLUSION: Fish oil combined with low-dose isotretinoin is noninferior and may preserve skin hydration and TG control.
OBJECTIVE: To compare the efficacy and safety of low-dose isotretinoin combined with fish oil versus low-dose isotretinoin monotherapy in moderate-to-severe acne.
METHODS: In this randomized, double-masked, controlled, non-inferiority trial, participants aged 18 to 25 years with an acne Investigator's Global Assessment (IGA) score ≥3 received 10-mg isotretinoin with 1-g fish oil (n = 40) or placebo (n = 40) once daily for 3 months. Outcomes included acne counts, IGA scores, skin biophysics, mucocutaneous adverse effects, serum triglyceride (TG), and liver transaminases.
RESULTS: The fish oil group was noninferior to the placebo group in reducing total acne counts from baseline (between-group mean difference: -6.0; 95% CI: -16.5 to 4.5). Fish oil also showed smaller reductions in corneometer values and smaller increases in TG levels.
LIMITATIONS: The use of IGA-based inclusion criteria may have influenced the non-inferiority analysis and the 3-month duration may limit long-term interpretation.
CONCLUSION: Fish oil combined with low-dose isotretinoin is noninferior and may preserve skin hydration and TG control.